Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | TRPC3 | Q13507 | 4/20 | 0.37 |
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539684 | 0.85 | PTGDR2 (0.48) | HTR2CTRPC3TRPC6SCD5PTGDR2 | |
| SCHEMBL3537833 | 0.83 | HTR2C (0.66) | HTR2CTRPC3TRPC6SCD5 | |
| SCHEMBL3543133 | 0.83 | HTR2C (0.66) | HTR2CTRPC3TRPC6SCD5 | |
| SCHEMBL3545036 | 0.82 | ALDH1A1 (0.46) | HTR2CTRPC3TRPC6 | |
| SCHEMBL5661659 | 0.81 | SCD5 (0.52) | HTR2CHCRTR1HCRTR2TRPC3TRPC6 | |
| SCHEMBL3536539 | 0.81 | HRH3 (0.39) | HTR2CHCRTR1HCRTR2HRH3GHSR | |
| SCHEMBL5661013 | 0.78 | HTR2C (0.63) | HTR2CHRH3 | |
| SCHEMBL5661113 | 0.78 | HTR2C (0.63) | HTR2CHRH3 | |
| SCHEMBL3542013 | 0.77 | HCRTR1 (0.48) | HTR2CHCRTR1HCRTR2HRH3GHSR | |
| SCHEMBL3542016 | 0.77 | HCRTR1 (0.48) | HTR2CHCRTR1HCRTR2HRH3GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | HTR2C 422/4885HCRTR1 2820/4885HCRTR2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.